COMMUNIQUÉS West-GlobeNewswire

National Lipid Association Announces Recipients of 2018-19 Junior Faculty Research Awards

06/07/2018 - 19:00

Nathan O. Stitziel, M.D., Ph.D., Soumik BasuRay, Ph.D., each earn two-year grant for lipid disorder research JACKSONVILLE, Fla., July 06, 2018 (GLOBE NEWSWIRE) -- The National Lipid Association announced on Friday the [...]

John Inadomi, MD is Honored by the American Health Council for “Best in Medicine”

06/07/2018 - 16:38

NEW YORK, July 06, 2018 (GLOBE NEWSWIRE) -- The American Health Council is proud to honor John Inadomi, MD as “America’s Best Doctor” for his contributions to the gastrointestinal field. Currently a professor of [...]

Abiomed First Quarter Fiscal 2019 Earnings And Conference Call Notification

06/07/2018 - 14:00

DANVERS, Mass., July 06, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc . (NASDAQ:ABMD) announced that on Thursday, July 26, 2018, the Company will release financial results for the first quarter of fiscal 2019. The Company will [...]

Barbara Nye, MD is Appointed to the American Health Council’s Board of Physicians

06/07/2018 - 14:00

NEW YORK, July 06, 2018 (GLOBE NEWSWIRE) -- The American Health Council proudly appointed Barbara Nye, MD to its Board of Physicians for her outstanding contributions to the medical field. Currently serving as co- [...]

GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 juin 2018

06/07/2018 - 13:45

Communiqué de presse Villepinte, le 6 juillet 2018 DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l'article L. 233-8 II du code de commerce et de l' [...]

Tauriga Sciences Inc. Receives Confirmation from FINRA that its Reverse Split will take Effect at Open of Trading Monday July 9, 2018; the Company’s Ticker Symbol will be Amended to “TAUGD” for a Period of 20 Business Days

06/07/2018 - 13:35

NEW YORK, NY, July 06, 2018 (GLOBE NEWSWIRE) -- Tauriga Sciences, Inc. (OTC PINK: TAUG) (OTC PINK: TAUGD) (“Tauriga” or the “Company”), engaged in building its business through the development, distribution, and [...]

AC Immune Announces Results of Annual General Meeting

06/07/2018 - 13:19

Lausanne, Switzerland, July 6, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that the shareholders of the Company have [...]

Major shareholder announcement

06/07/2018 - 13:03

Orphazyme A/S Company announcement No. 09/2018 Company Registration No. 32266355 Copenhagen, July 6, 2018 – Orphazyme A/S (the “ Company ”), a biopharmaceutical company dedicated to developing treatments for patients [...]

Auxly Announces Upgrade on OTC Markets to OTCQX

06/07/2018 - 13:00

VANCOUVER, British Columbia, July 06, 2018 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX.V:XLY) (" Auxly " or the " Company ") is pleased to announce that effective today, July 6, 2018, the Company's common shares [...]

Cannabis Act Regulations Indicative of Radient Technologies’ Role in Industrial-Scale Cannabis and Hemp Value Chains

06/07/2018 - 12:59

EDMONTON, Alberta, July 06, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture:RTI), is encouraged by Health Canada’s recently introduced Cannabis Regulations and Industrial [...]

RAMSAY GENERALE DE SANTE : Financement - Fiducie sûreté

06/07/2018 - 10:11

Paris, le 5 juillet 2018 « Communiqué de Presse » Financement - Fiducie Sûreté Immobilière de Santé , la principale holding de détention des participations en titres et/ou en actifs immobiliers du groupe Ramsay Générale [...]

Orion has started a Phase III trial to develop a drug for ALS - The patient recruitment has begun

06/07/2018 - 10:00

ORION CORPORATION PRESS RELEASE 6 JULY 2018 AT 11.00 EEST Orion has started a Phase III trial to develop a drug for ALS - The patient recruitment has begun Orion has recruited the first patients in the Phase III [...]

CellaVision AB presents the second quarter 2018 on July 17 at 11:00 CET

06/07/2018 - 08:21

The information was submitted to the public on July 6, 2018 at 8:20 CET CellaVision AB (publ) will publish the interim report for the first quarter on July 17, 2018 at 8:20 CET. The report will be available at www. [...]

Herantis Pharma initiates non-invasive CDNF development program, announces licensing agreement with University of Helsinki

06/07/2018 - 08:01

Herantis Pharma initiates non-invasive CDNF development program, announces licensing agreement with University of Helsinki Herantis Pharma Plc Company release 6 Jul 2018 at 9:00 am Herantis Pharma Plc ("Herantis") [...]

ObsEva SA Shares to Begin Trading on SIX Swiss Exchange

06/07/2018 - 07:31

Listing of 45'381'252 registered shares with a par value of 1/13 of CHF 1 per share Anticipated market capitalisation of more than CHF 650 million Trading on SIX Swiss Exchange scheduled for July 13, 2018 under the [...]

Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid

06/07/2018 - 07:01

PRESS RELEASE Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid in respect of TiGenix and Commencement of Simplified Squeeze-out and Intention to [...]

Takeda et TiGenix annoncent les résultats de la deuxième période d'acceptation pour l'offre publique d'acquisition volontaire et conditionnelle de TiGenix

06/07/2018 - 07:01

COMMUNIQUÉ DE PRESSE Takeda et TiGenix annoncent les résultats de la deuxième période d'acceptation pour l'offre publique d'acquisition volontaire et conditionnelle de TiGenix, le début du retrait simplifié et son [...]

Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months

06/07/2018 - 01:30

The final analysis at 18 months of the 856 patient Phase II clinical study in early Alzheimer’s disease demonstrated statistically significant slowing in clinical decline and reduction of amyloid beta accumulated in the [...]

LADAVRU® NEWS “HOVERINK BIOTECHNOLOGIES SEEKS COMMERCIAL PARTNERING OPPORTUNITIES IN ONCOLOGY SUPPORTIVE THERAPIES AND SEEKS A COMMERCIALIZATION AGREEMENT FOR ITS INVESTIGATIONAL DRUG LADAVRU®”

06/07/2018 - 01:20

LOS ANGELES, CA, July 05, 2018 (GLOBE NEWSWIRE) -- HOVERINK BIOTECHNOLOGIES , seeks to enter into a licensing agreement for the exclusive rights to commercialize LADAVRU(TM) (Dronabinol for injection) and an oral [...]